

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 31/70, 39/39, C07H 21/00</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/61151</b> <b>(43) International Publication Date:</b> 19 October 2000 (19.10.00)
<b>(21) International Application Number:</b> PCT/US00/09839 <b>(22) International Filing Date:</b> 12 April 2000 (12.04.00)  <b>(30) Priority Data:</b> 60/128,898      12 April 1999 (12.04.99)      US  <b>(71) Applicant (for all designated States except US):</b> THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; National Institutes of Health Office of Technology Transfer, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> KLINMAN, Dennis [US/US]; 2 Candlelight Court, Potomac, MD 20854 (US). ISHII, Ken [JP/US]; 257 Congressional Lane #120, Rockville, DM 20852 (US). VERTHELYI, Daniela [AR/US]; 11615 Regency Drive, Potomac, MD 20854 (US).  <b>(74) Agents:</b> GAGALA, Bruce, M. et al.; Leydig, Voit & Mayer, Ltd., Suite 4900, Two Prudential Plaza, 180 North Stetson, Chicago, IL 60601-6780 (US).		<b>(81) Designated States:</b> AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> OLIGODEOXYNUCLEOTIDE AND ITS USE TO INDUCE AN IMMUNE RESPONSE  <b>(57) Abstract</b>  The present invention provides a substantially pure or isolated oligodeoxynucleotide of at least about 10 nucleotides comprising a sequence represented by either the formula: 5' N <sub>1</sub> N <sub>2</sub> N <sub>3</sub> T-CpG-WN <sub>4</sub> N <sub>5</sub> N <sub>6</sub> 3' wherein the central CpG motif is unmethylated, W is A or T, and N <sub>1</sub> , N <sub>2</sub> , N <sub>3</sub> , N <sub>4</sub> , N <sub>5</sub> , and N <sub>6</sub> are any nucleotides, or the formula: 5' RY-CpG-RY 3' wherein the central CpG motif is unmethylated, R is A or G, and Y is C or T, as well as an oligodeoxynucleotide delivery complex and a pharmacological composition comprising the present inventive oligodeoxynucleotide, and a method of inducing an immune response by administering the present inventive oligodeoxynucleotide to a host.		

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## OLIGODEOXYNUCLEOTIDE AND ITS USE TO INDUCE AN IMMUNE RESPONSE

### TECHNICAL FIELD OF THE INVENTION

- 5           The present invention relates generally to induction of an immune response using specific oligodeoxynucleotides (ODNs).

### BACKGROUND OF THE INVENTION

- DNA is a complex macromolecule whose immunological activities are  
10   influenced by its base composition and base modification, as well as helical orientation. Certain unusual DNA structures (e.g., Z-DNA) can induce significant antibody responses when administered to normal mice. In addition, bacterial DNA, as well as certain synthetic ODNs containing unmethylated CpG sequences can induce proliferation and immunoglobulin (Ig) production by murine B cells. Unmethylated  
15   CpG dinucleotides are more frequent in the genomes of bacteria and viruses than vertebrates. Recent studies suggest that immune recognition of these motifs may contribute to the host's innate immune response. D.M. Klinman et al., *CpG Motifs Present in Bacterial DNA Rapidly Induce Lymphocytes to Secrete Interleukin 6, Interleukin 12, and Interferon  $\gamma$* , 93 Proc. Natl. Acad. Sci. USA 2879 (1996); A.-K. Yi et al., *Rapid Immune Activation by CpG Motifs in Bacterial DNA*, 157 J. Immun. 5394  
20   (1996); Hua Liang et al., *Activation of Human B Cells by Phosphorothioate Oligodeoxynucleotides*, 98 J. Clin. Invest. 1119 (1996); A.M. Krieg et al., *CpG Motifs in Bacterial DNA Trigger Direct B-Cell Activation*, 374 Nature 546 (1995).

- In mice, CpG DNA induces proliferation in almost all (>95%) of B cells and  
25   increases Ig secretion. This B-cell activation by CpG DNA is T-cell independent and antigen non-specific. In addition to its direct effects on B cells, CpG DNA also directly activates monocytes, macrophages, and dendritic cells to secrete a variety of cytokines. These cytokines stimulate natural killer (NK) cells to secrete  $\gamma$ -interferon (IFN- $\gamma$ ) and have increased lytic activity. Examples of which can be found in  
30   International Patent Applications WO 95/26204, WO 96/02555, WO 98/11211, WO 98/18810, WO 98/37919, WO 98/40100, WO 98/52581, PCT/US98/047703, and PCT/US99/07335; U.S. Patent No. 5,663,153; and U.S. Patent Applications Serial

Nos. 08/276,358, 08/386,063, 08/461,036, 08/462/799, 08/960,774, 08/738,652, 09/030,701, 09/082,649, 09/191,170, 09/ 09/136,138, 09/154,614, and 09/286,098.

Although bacterial DNA and certain ODNs can induce a murine immune response, little is known about the immunostimulatory capacity of these materials for the human immune system. Z.K. Ballas et al., *Induction of NK Activity in Murine and Human Cells by CpG Motifs in Oligodeoxynucleotides and Bacterial DNA*, 157 J. Immun. 1840 (1996). Differences in the responsiveness of human and murine B cells to certain stimuli render it impossible to extrapolate results obtained from mouse to man.

10 In view of the above, there exists a need for ODNs that induce an immune response in humans. In addition, there is a need for methods utilizing ODNs in the treatment of human diseases. The present invention provides such ODNs and methods of use. These and other advantages of the present invention, as well as additional inventive features, will be apparent from the description of the invention  
15 provided herein.

#### BRIEF SUMMARY OF THE INVENTION

The present invention provides a substantially pure or isolated ODN of at least about 10 nucleotides comprising a sequence represented by either the formula:

20



wherein the central CpG motif is unmethylated, W is A or T, and N<sub>1</sub>, N<sub>2</sub>, N<sub>3</sub>, N<sub>4</sub>, N<sub>5</sub>, and N<sub>6</sub> are any nucleotides, or the formula:

25



wherein the central CpG motif is unmethylated, R is A or G, and Y is C or T. The present invention also provides an ODN delivery complex and pharmacological  
30 composition comprising the present inventive ODN, as well as a method of inducing an immune response by administering the present inventive ODN to a host.

## DETAILED DESCRIPTION OF THE INVENTION

*Oligodeoxynucleotide*

The present invention provides novel ODNs. These ODNs have at least about 10 nucleotides and comprise a sequence represented by either the formula:

5



wherein the central CpG motif is unmethylated, W is A or T, and N<sub>1</sub>, N<sub>2</sub>, N<sub>3</sub>, N<sub>4</sub>, N<sub>5</sub>, and N<sub>6</sub> are any nucleotides, or the formula:

10



wherein the central CpG motif is unmethylated, R is A or G, and Y is C or T. For example, the ODN can be selected from the group consisting of SEQ ID NO: 1

15

through SEQ ID NO: 99.

Preferably, the ODN of the present invention is substantially pure or isolated. "Substantially pure" refers to an ODN that is substantially free of other materials, particularly other nucleic acids, proteins, lipids, carbohydrates, and other materials with which it may be naturally associated, while "isolated" refers to an ODN that is removed from its natural environment or state. Preferably, the ODN of the present invention consists of about 100 nucleotides or less (e.g., about 10-75 nucleotides). More preferably, the ODN consists of about 50 nucleotides or less (e.g., about 10-40 nucleotides). Even more preferably, the ODN consists of about 30 nucleotides or less (e.g., about 10-20 nucleotides). Most preferably the ODN consists of about 12 to about 16 nucleotides.

20

25

Any suitable modification can be used in the present invention to render the ODN resistant to degradation *in vivo* (e.g., via an exo or endonuclease). Preferably, the modification includes a phosphorothioate modification. The phosphorothioate modifications can occur at either termini, e.g., the last two or three 5' and/or 3' nucleotides can be linked with phosphorothioate bonds. The ODN also can be modified to contain a secondary structure (e.g., stem loop structure) such that it is resistant to degradation. Another modification that renders the ODN less susceptible

30

to degradation is the inclusion of nontraditional bases such as inosine and quesine, as well as acetyl-, thio- and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine. Other modified nucleotides include nonionic DNA analogs, such as alkyl or aryl phosphonates (i.e., the charged phosphonate oxygen is replaced  
5 with an alkyl or aryl group, as set forth in U.S. Patent No. 4,469,863), phosphodiester and alkylphosphotriesters (i.e., the charged oxygen moiety is alkylated, as set forth in U.S. Patent No. 5,023,243 and European Patent No. 0 092 574). ODNs containing a diol, such as tetraethyleneglycol or hexaethyleneglycol, at either or both termini, have also been shown to be more resistant to degradation.

10 Preferably, the ODNs inducing a humoral immune response, e.g., 5' N<sub>1</sub>N<sub>2</sub>N<sub>3</sub>T-CpG-WN<sub>4</sub>N<sub>5</sub>N<sub>6</sub> 3', contain a phosphate backbone modification, and more preferably, the phosphate backbone modification is a phosphorothioate backbone modification (i.e., one of the non-bridging oxygens is replaced with sulfur, as set forth in International Patent Application WO 95/26204). For the ODNs  
15 inducing a cell-mediated immune response and containing a phosphodiester backbone, e.g., 5' RY-CpG-RY 3', the ODN preferably has been modified to prevent degradation.

#### *Oligodeoxynucleotide Delivery Complex*

20 The present inventive oligodeoxynucleotide delivery complex comprises the present inventive ODN and a targeting means. Any suitable targeting means can be used within the context of the present invention.

An ODN can be associated with (e.g., ionically or covalently bound to, or encapsulated within) a targeting means (e.g., a molecule that results in higher affinity  
25 binding to a target cell, such as a B cell). A variety of coupling or cross-linking agents can be used to form the delivery complex, such as protein A, carbodiimide, and N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP). Examples of ODN delivery complexes include ODNs associated with a sterol (e.g., cholesterol), a lipid (e.g., a cationic lipid, virosome or liposome), and a target cell specific binding agent  
30 (e.g., a ligand recognized by target cell specific receptor). Preferred complexes must be sufficiently stable *in vivo* to prevent significant uncoupling prior to internalization

by the target cell; however, these complexes can be cleavable under appropriate circumstances such that the ODN can be released in a functional form.

### *Pharmacological Composition*

5           The present inventive pharmacological composition comprises the present inventive ODN and a pharmacologically acceptable carrier. Pharmacologically acceptable carriers (e.g., physiologically or pharmaceutically acceptable carriers) are well known in the art.

10           The present inventive pharmacological composition facilitates the use of the present inventive ODN, both *in vivo* and *ex vivo*. Such a composition can be suitable for delivery of the active ingredient to any suitable host, such as a patient for medical application, and can be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

15           Pharmacological compositions for use in accordance with the present invention can be formulated in a conventional manner using one or more pharmacologically (e.g., physiologically or pharmaceutically) acceptable carriers comprising excipients, as well as optional auxiliaries that facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper  
20           formulation is dependent upon the route of administration chosen. Thus, for injection, the active ingredient can be formulated in aqueous solutions, preferably in physiologically compatible buffers. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art. For oral administration, the active  
25           ingredient can be combined with carriers suitable for inclusion into tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like. For administration by inhalation, the active ingredient is conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant. The active ingredient can be formulated for parenteral  
30           administration by injection, e.g., by bolus injection or continuous infusion. Such compositions can take such forms as suspensions, solutions or emulsions in oily or

aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Other pharmacological excipients are known in the art.

#### *Method of Inducing an Immune Response*

5           The present inventive method of inducing an immune response comprises administering the present inventive ODN to a host in order to induce an immune response in the host.

Administration of the present inventive ODN can be by any suitable method. For example, the ODN can be administered *in vivo* or *ex vivo*. Preferably, the ODN is  
10 administered *in vivo* to a mammal, particularly a human. Optionally, the ODN can be contained within or conjugated with a protein, hydrocarbon or lipid. Once this molecule is administered, the ODN sequence must be exposed on the surface to induce an immune response. The ODN can also be co-administered with a protein, hydrocarbon, or lipid. Co-administration can be such that the ODN is administered  
15 before, at substantially the same time as, or after the protein, hydrocarbon, or lipid. Preferably, the ODN is administered at substantially the same time as the protein, hydrocarbon, or lipid.

After administration of the novel ODNs, while not intending to be bound by any particular theory, it is thought that the ODNs initially act on antigen presenting  
20 cells (e.g., macrophages and dendritic cells). These cells then release cytokines, which activate natural killer (NK) cells. Either a cell-mediated or humoral immune response then occurs in the host.

The cell-mediated or local immune response is produced by T cells, which are able to detect the presence of invading pathogens through a recognition system  
25 referred to as the T-cell antigen receptor. Upon detection of an antigen, T cells direct the release of multiple T-cell cytokines, including IL-2, IL-3, IFN- $\gamma$ , TNF- $\beta$ , GM-CSF and high levels of TNF- $\alpha$ , and chemokines MIP-1 $\alpha$ , MIP-1 $\beta$ , and RANTES. IL-2 is a T-cell growth factor that promotes the production of additional T cells sensitive to the particular antigen. This production constitutes a clone of the T cells. The sensitized  
30 T cells attach to cells containing the antigen. T cells carry out a variety of regulatory and defense functions and play a central role in immunologic responses. When stimulated to produce a cell-mediated immune response, some T cells respond by



acting as killer cells, killing the host's own cells when these cells are infected or cancerous and therefore recognized as foreign. Some T cells respond by stimulating B cells, while other T cells respond by suppressing immune response. Preferably, if a cell-mediated immune response is induced, non-B cells are activated, more preferably, cytokines are produced, and most preferably, IFN- $\gamma$  is produced.

The humoral or systemic immune response depends on the ability of the B cells to recognize specific antigens. The mechanism by which B cells recognize antigens is through specific receptors on the surface of the B cells. When an antigen attaches to the receptor site of a B cell, the B cell is stimulated to divide. The daughter cells become plasma cells that manufacture antibodies complementary to the attached antigen. Each plasma cell produces thousands of antibody molecules per minute, which are released into the bloodstream. Many B cells appear to be regulated by the helper T cells and suppressor T cells and produce various cytokines, e.g., IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, GM-CSF and low levels of TNF- $\alpha$ . Helper T cells stimulate B cells to produce antibodies against antigens, while suppressor T cells inhibit antibody production. Some B cells, however, are T-cell independent and require no stimulation by the T cells. Preferably, if a humoral immune response is induced, B cells are activated, more preferably, IL-6 is produced, and most preferably, antibodies are produced.

In addition, induction of one type of immune response may allow for immune regulation because up regulation of one type of immune response may down regulate the other type of immune response. This immune regulation allows for customizing or tailoring of the type of immune response when administering an ODN.

The present inventive method can be used to treat, prevent, or ameliorate any suitable allergic reaction in combination with any suitable anti-allergenic agent. An allergy, in the context of the present invention, refers to an acquired hypersensitivity to a substance (i.e., an allergen). Allergic conditions include eczema, allergic rhinitis or coryza, hay fever, bronchial asthma, urticaria (hives), food allergies, and other atopic conditions. The list of allergens is extensive and includes pollens, insect venoms, animal dander, dust, fungal spores, and drugs (e.g., penicillin). Examples of natural, animal, and plant allergens can be found in International Patent Application WO 98/18810. Preferably, the present inventive method is used to treat allergic

asthma. Suitable anti-allergenic agents include those substances given in treatment of the various allergic conditions described above, examples of which can be found in the Physicians' Desk Reference (1998).

5 The present inventive method can be used to treat any suitable cancer in combination with any suitable anti-cancer agent. Suitable cancers include cancers of the brain, lung (e.g., small cell and non-small cell), ovary, breast, prostate, and colon, as well as carcinomas and sarcomas. Preferably, the present inventive method is used to treat a solid tumor cancer. Suitable anti-cancer agents include those substances given in treatment of the various conditions described above, examples of which can  
10 be found in the Physicians' Desk Reference (1998).

The present inventive method can be used to improve the efficacy of any suitable vaccine. Suitable vaccines include those directed against Hepatitis A, B, and C, examples of which can be found in the Physicians' Desk Reference (1998), and DNA vaccines directed against HIV and malaria. *See generally* D. Klinman et al.,  
15 *CpG Motifs as Immune Adjuvants*, 17 Vaccine 19 (1999); M.J. McCluskie and H.L. Davis, *CpG DNA is a Potent Enhancer of Systemic & Mucosal Immune Response Against Hepatitis B Surface Antigen with Intra-Nasal Administration to Mice*, 161 J. Immun. 4463 (1998).

The present inventive method can be used to treat, prevent, or ameliorate any  
20 suitable disease associated with the immune system. Preferred diseases associated with the immune system are autoimmune disorders and immune system deficiencies, e.g., lupus erythematosus, and autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Immune system deficiencies include those diseases or disorders in which the immune system is not functioning at normal capacity, or in which it would  
25 be useful to boost the immune system response.

The present inventive method can be used with any suitable antisense therapy. Suitable antisense agents are those that bind either with DNA or RNA and block their function by inhibiting expression of the sequence to which the antisense agents are bound. *See generally* H. Lonnberg et al., *Towards Genomic Drug Therapy with*  
30 *Antisense Oligonucleotides*, 28 Ann. Med. 511 (1996); A. Alama et al., *Antisense Oligonucleotides as Therapeutic Agents*, 36 Pharmacol. Res. 171 (1997); K.J. Scanlon et al., *Oligonucleotide-Mediated Modulation of Mammalian Gene Expression*, 9

FASEB J. 1288 (1995); R. Oberbauer, *Not Non-Sense but Antisense – Applications of Antisense Oligonucleotides in Different Fields of Medicine*, 109 Wien Klin Wochenschr 40 (1997).

5 The present inventive method can be used to treat, prevent, or ameliorate any suitable infection in combination with any suitable anti-infectious agent. Examples include francisella, schistosomiasis, tuberculosis, AIDS, malaria, and leishmania. Examples of suitable infectious viruses, bacteria, fungi, and other organisms (e.g., protists) can be found in International Patent Application WO 98/18810. Suitable anti-infectious agents include those substances given in treatment of the various  
10 conditions described elsewhere, examples of which can be found in the Physicians' Desk Reference (1998).

The present inventive method can be used to treat, prevent, or ameliorate the symptoms resulting from exposure to a bio-warfare agent. Suitable bio-warfare agents include those naturally occurring biological agents that have been specifically  
15 modified in the laboratory. Often, modification of these agents has altered them such that there is no known treatment. Examples include Ebola, Anthrax, and Listeria. In the course of ameliorating the symptoms after exposure, use of the present inventive ODNs may not cure the patient, but rather can extend the patient's life sufficiently such that some other treatment can then be applied.

20 The present invention is further described in the following examples. These examples are intended only to illustrate the invention and are not intended to limit the scope of the invention in any way.

## EXAMPLES

### 25 *Example 1*

The following example demonstrates induction of an immune response by various ODNs. Induction was measured by production of the cytokines IL-6 and TNF- $\gamma$ , and cell proliferation.

Human peripheral blood mononuclear cells (PBMC) were isolated, as  
30 described elsewhere (Z.K. Ballas et al., 85 J. Allergy Clin. Immunol. 453 (1990); Z.K. Ballas and W. Rasmussen, 45 J. Immunol. 1039 (1990); Z.K. Ballas and W. Rasmussen, 150 J. Immunol. 17 (1993)). ODNs were synthesized on a DNA

synthesizer (Applied Biosystems Inc., Foster City, CA), as described elsewhere (Beacage and Caruthers, *Deoxynucleoside Phosphoramidites – A New Class of Key Intermediates for Deoxypolynucleotide Synthesis*, 22 Tetrahedron Letters 1859 (1981)). In some ODNs, the normal DNA backbone phosphodiesterase linkages were replaced with phosphorothioate linkages, as described elsewhere (Agrawal et al., 94 Proc. Natl. Acad. Sci. USA 2620 (1997); Agrawal 14 TIB TECH 376 (1996)). To reduce degradation of the ODNs, those that did not have an entire phosphorothioate backbone contained phosphorothioate linkages at the 5' and 3' ends. Cells were incubated for approximately 72 hrs with the various ODNs. IL-6 and TNF- $\gamma$  levels were determined by ELISA using anti-IL-6 and anti-TNF- $\gamma$  antibodies, as described elsewhere (Maniatis et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, New York, 1989). Cell proliferation was determined by [ $^3$ H] thymidine incorporation, as described elsewhere (Liang et al., 98 J. Clin. Invest. at 1121).

IL-6 levels and cell proliferation are set forth in Table 1: Induction of a Humoral Immune Response *In Vitro*. These data demonstrate that a sequence containing 5' N<sub>1</sub>N<sub>2</sub>N<sub>3</sub>T-CpG-WN<sub>4</sub>N<sub>5</sub>N<sub>6</sub> 3', wherein the central CpG motif is unmethylated, W is A or T, and N<sub>1</sub>, N<sub>2</sub>, N<sub>3</sub>, N<sub>4</sub>, N<sub>5</sub>, and N<sub>6</sub> are any nucleotides, is desirable to induce a humoral immune response. In addition, maximum induction was observed for ODNs that contained a phosphorothioate backbone. IFN- $\gamma$  levels and cell proliferation are set forth in Table 2: Induction of a Cell-Mediated Immune Response *In Vitro*. These data demonstrate that a sequence containing 5' RY-CpG-RY 3', wherein the central CpG motif is unmethylated, R is A or G and Y is C or T, is desirable to induce a cell-mediated immune response. Maximum induction occurred with ODNs containing phosphodiesterase linkages.

Table 1. Induction of a Humoral Immune Response *In Vitro*.

	IL-6 Levels (ELISA)	Cell Proliferation ( $^3$ H Thymidine Incorporation)
SEQ ID NO: 1	65	52
SEQ ID NO: 2	85	44
SEQ ID NO: 3	54	50

	IL-6 Levels (ELISA)	Cell Proliferation ( <sup>3</sup> H Thymidine Incorporation)
SEQ ID NO: 4	48	61
SEQ ID NO: 5	42	100
SEQ ID NO: 6	55	23
SEQ ID NO: 7	35	69
SEQ ID NO: 8	28	38
SEQ ID NO: 9	41	20
SEQ ID NO: 10	42	16
SEQ ID NO: 11	33	77
SEQ ID NO: 12	25	13
SEQ ID NO: 13	28	13
SEQ ID NO: 14	35	67
SEQ ID NO: 15	28	54
SEQ ID NO: 16	39	50
SEQ ID NO: 17	50	32
SEQ ID NO: 18	26	1
SEQ ID NO: 19	12	2
SEQ ID NO: 20	55	92
SEQ ID NO: 21	53	26
SEQ ID NO: 22	8	2
SEQ ID NO: 23	12	1
SEQ ID NO: 24	14	0
SEQ ID NO: 25	30	42
SEQ ID NO: 26	43	60
SEQ ID NO: 27	17	15
SEQ ID NO: 28	14	0
SEQ ID NO: 29	10	1
SEQ ID NO: 30	28	23
SEQ ID NO: 31	16	17

Table 2. Induction of a Cell-Mediated Immune Response *In Vitro*.

	IFN- $\gamma$ Levels (ELISA)	Cell Proliferation ( <sup>3</sup> H Thymidine Incorporation)
SEQ ID NO: 32	78	1
SEQ ID NO: 33	100	2
SEQ ID NO: 34	73	2
SEQ ID NO: 35	88	4

	IFN- $\gamma$ Levels (ELISA)	Cell Proliferation ( $^3$ H Thymidine Incorporation)
SEQ ID NO: 36	81	5
SEQ ID NO: 37	45	4
SEQ ID NO: 38	78	0
SEQ ID NO: 39	33	5
SEQ ID NO: 40	68	2
SEQ ID NO: 41	54	2
SEQ ID NO: 42	54	1
SEQ ID NO: 43	74	4
SEQ ID NO: 44	53	4
SEQ ID NO: 45	32	9
SEQ ID NO: 46	24	1
SEQ ID NO: 47	23	8
SEQ ID NO: 48	22	25
SEQ ID NO: 49	34	26
SEQ ID NO: 50	36	8
SEQ ID NO: 51	24	17
SEQ ID NO: 52	21	9
SEQ ID NO: 53	19	2
SEQ ID NO: 54	12	8
SEQ ID NO: 55	15	5
SEQ ID NO: 56	22	6
SEQ ID NO: 57	18	3
SEQ ID NO: 58	18	6
SEQ ID NO: 59	12	21
SEQ ID NO: 60	13	4
SEQ ID NO: 61	--	2
SEQ ID NO: 62	12	23
SEQ ID NO: 63	16	1
SEQ ID NO: 64	16	4
SEQ ID NO: 65	19	2
SEQ ID NO: 66	16	4
SEQ ID NO: 67	14	2
SEQ ID NO: 68	13	1
SEQ ID NO: 69	12	2
SEQ ID NO: 70	19	2
SEQ ID NO: 71	13	1
SEQ ID NO: 72	14	46
SEQ ID NO: 73	--	4
SEQ ID NO: 74	16	1
SEQ ID NO: 75	24	1

	IFN- $\gamma$ Levels (ELISA)	Cell Proliferation ( $^3\text{H}$ Thymidine Incorporation)
SEQ ID NO: 76	13	1
SEQ ID NO: 77	12	1
SEQ ID NO: 78	13	1
SEQ ID NO: 79	13	1
SEQ ID NO: 80	12	1
SEQ ID NO: 81	14	20
SEQ ID NO: 82	14	43
SEQ ID NO: 83	14	1
SEQ ID NO: 84	12	1
SEQ ID NO: 85	15	2
SEQ ID NO: 86	13	1
SEQ ID NO: 87	12	0
SEQ ID NO: 88	—	3
SEQ ID NO: 89	15	1
SEQ ID NO: 90	18	2
SEQ ID NO: 91	13	2
SEQ ID NO: 92	12	1
SEQ ID NO: 93	14	2
SEQ ID NO: 94	14	1
SEQ ID NO: 95	44	3
SEQ ID NO: 96	24	1
SEQ ID NO: 97	21	6
SEQ ID NO: 98	36	38
SEQ ID NO: 99	21	26

The foregoing data demonstrates the induction of an immune response in human cells, as exemplified by PBMC, and as measured by the production of the cytokines IFN- $\gamma$  and IL-6, and cell proliferation, occurs upon the administration of various ODNs.

### Example 2

The following example demonstrates induction of an immune response *ex vivo* by various ODNs. Induction was measured by production of the cytokine IL-6.

10 A human B cell line (RPMI 8226) was maintained according to the manufacturers recommendations. ODNs were synthesized as described in Example 1. In some ODNs, the normal DNA phosphodiesterase linkages were replaced with

phosphorothioate linkages, as described in Example 1. To reduce degradation of the ODNs, those that did not have an entire phosphorothioate backbone contained phosphorothioate linkages at the ends. The cells were incubated with various ODNs for 14 hrs. IL-6 production was determined by ELISA using anti-IL-6 antibodies, as

5 described in Example 1.

IL-6 levels are set forth in Table 3: Induction of a Humoral Immune Response *Ex Vivo*. These data confirm that a sequence containing 5' N<sub>1</sub>N<sub>2</sub>N<sub>3</sub>T-CpG-WN<sub>4</sub>N<sub>5</sub>N<sub>6</sub> 3', which are linked by phosphorothioate bonds and wherein the central CpG motif is unmethylated, W is A or T, and N<sub>1</sub>, N<sub>2</sub>, N<sub>3</sub>, N<sub>4</sub>, N<sub>5</sub>, and N<sub>6</sub> are any nucleotides, is

10 desirable to induce a humoral immune response.

Table 3. Induction of a Humoral Immune Response *Ex Vivo*.

	IL-6 Levels (ELISA)
SEQ ID NO: 1	100
SEQ ID NO: 2	89
SEQ ID NO: 3	85
SEQ ID NO: 4	82
SEQ ID NO: 5	82
SEQ ID NO: 6	78
SEQ ID NO: 7	78
SEQ ID NO: 8	78
SEQ ID NO: 9	73
SEQ ID NO: 10	65
SEQ ID NO: 11	62
SEQ ID NO: 12	58
SEQ ID NO: 13	57
SEQ ID NO: 14	56
SEQ ID NO: 15	50
SEQ ID NO: 16	48
SEQ ID NO: 17	47
SEQ ID NO: 18	45
SEQ ID NO: 19	40
SEQ ID NO: 20	39
SEQ ID NO: 21	33
SEQ ID NO: 22	25
SEQ ID NO: 23	23



	IL-6 Levels (ELISA)
SEQ ID NO: 24	21
SEQ ID NO: 25	18
SEQ ID NO: 26	17
SEQ ID NO: 27	17
SEQ ID NO: 28	16
SEQ ID NO: 29	16
SEQ ID NO: 30	13
SEQ ID NO: 31	13

The foregoing data demonstrates the induction of an immune response in human cells, as exemplified by the human B cell line RPMI 8226, and as measured by production of the cytokine IL-6, occurs upon administration of various ODNs.

5

The following table lists additional ODNs which fall within the scope of the present invention.

Table 4:

10

SEQ ID NO: 100
SEQ ID NO: 101
SEQ ID NO: 102
SEQ ID NO: 103
SEQ ID NO: 104
SEQ ID NO: 105
SEQ ID NO: 106
SEQ ID NO: 107
SEQ ID NO: 108
SEQ ID NO: 109
SEQ ID NO: 110
SEQ ID NO: 111
SEQ ID NO: 112
SEQ ID NO: 113
SEQ ID NO: 114
SEQ ID NO: 115
SEQ ID NO: 116
SEQ ID NO: 117

---

SEQ ID NO: 118  
SEQ ID NO: 119  
SEQ ID NO: 120  
SEQ ID NO: 121  
SEQ ID NO: 122  
SEQ ID NO: 123  
SEQ ID NO: 124  
SEQ ID NO: 125  
SEQ ID NO: 126  
SEQ ID NO: 127  
SEQ ID NO: 128  
SEQ ID NO: 129  
SEQ ID NO: 130  
SEQ ID NO: 131  
SEQ ID NO: 132  
SEQ ID NO: 133  
SEQ ID NO: 134  
SEQ ID NO: 135  
SEQ ID NO: 136  
SEQ ID NO: 137  
SEQ ID NO: 138  
SEQ ID NO: 139  
SEQ ID NO: 140  
SEQ ID NO: 141  
SEQ ID NO: 142  
SEQ ID NO: 143

---

All of the references cited herein, including patents, patent applications, and publications, are hereby incorporated in their entireties by reference.

5 While this invention has been described with an emphasis upon preferred embodiments, it will be obvious to those of ordinary skill in the art that variations of the preferred embodiments may be used and it is intended that the invention may be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications encompassed within the spirit and scope of the invention as defined by the following claims.

## WHAT IS CLAIMED IS:

1. A substantially pure or isolated oligodeoxynucleotide of at least about 10 nucleotides comprising a sequence represented by the following formula:

5



wherein the central CpG motif is unmethylated, W is A or T, and N<sub>1</sub>, N<sub>2</sub>, N<sub>3</sub>, N<sub>4</sub>, N<sub>5</sub>, and N<sub>6</sub> are any nucleotides.

10

2. A substantially pure or isolated oligodeoxynucleotide of at least about 10 nucleotides comprising a sequence represented by the following formula:



15

wherein the central CpG motif is unmethylated, R is A or G and Y is C or T.

3. The oligodeoxynucleotide of claim 2, wherein the sequences on the 5' side of the CpG sequences form a palindrome with the sequences on the 3' side of the CpG sequence.

20

4. The oligodeoxynucleotide of any of claims 1-3, wherein the oligodeoxynucleotide is selected from the group consisting of SEQ ID NO: 1 through SEQ ID NO: 143.

25

5. The oligodeoxynucleotide of any of claims 1-4, wherein the oligodeoxynucleotide is modified to prevent degradation.

6. The oligodeoxynucleotide of any of claims 1-5, wherein the oligodeoxynucleotide has a phosphate backbone modification.

30

7. The oligodeoxynucleotide of claim 6, wherein the phosphate backbone modification is a phosphorothioate backbone modification.
8. The oligodeoxynucleotide of any of claims 1-7, wherein the  
5 oligodeoxynucleotide comprises about 100 nucleotides or less.
9. The oligodeoxynucleotide claim 8, wherein the oligodeoxynucleotide comprises about 50 nucleotides or less.
- 10 10. The oligodeoxynucleotide of claim 9, wherein the oligodeoxynucleotide comprises about 30 nucleotides or less.
11. The oligodeoxynucleotide of claim 10, wherein the oligodeoxynucleotide comprises about 12-16 nucleotides.  
15
12. An oligodeoxynucleotide delivery complex comprising the oligodeoxynucleotide of any of claims 1-11 and a targeting means.
13. The oligodeoxynucleotide delivery complex of claim 12, wherein the  
20 targeting means is selected from the group consisting of cholesterol, virosome, liposome, lipid, and a target cell specific binding agent.
14. A pharmacological composition comprising the oligodeoxynucleotide of any of claims 1-11 and a pharmacologically acceptable carrier.  
25
15. A method of inducing an immune response in a host comprising administering to a host an oligodeoxynucleotide of any of claims 1-11.
16. The method of claim 15, wherein the immune response induced is a  
30 cell-mediated immune response.

17. The method of claim 15 or 16, wherein the oligodeoxynucleotide activates non-B cells in the host.

18. The method of any of claims 15-17, wherein the oligodeoxynucleotide induces cytokine production in the host.

19. The method of claim 18, wherein the cytokine is IFN- $\gamma$ .

20. The method of claim 15, wherein the immune response induced is a humoral immune response.

21. The method of claim 15 or 20, wherein the oligodeoxynucleotide activates B cells in the host.

22. The method of any of claims 15, 20, or 21, wherein the oligodeoxynucleotide induces IL-6 production in the host.

23. The method of any of claims 15, 20-22, wherein the oligodeoxynucleotide induces antibody production in the host.

24. The method of any of claims 15-23, wherein the induction of an immune response is used to treat, prevent, or ameliorate an allergic reaction, and the oligodeoxynucleotide is administered either alone or in combination with an anti-allergenic agent.

25. The method of claim 24, wherein the allergic reaction is asthmatic.

26. The method of any of claims 15-23, wherein the induction of an immune response is used to treat cancer, and the oligodeoxynucleotide is administered either alone or in combination with an anti-cancer agent.

27. The method of claim 26, wherein the cancer is a solid tumor cancer.

28. The method of any of claims 15-23, wherein the induction of an immune response is used to improve the efficacy of a vaccine, and the oligodeoxynucleotide is administered either alone or in combination with a vaccine.
- 5
29. The method of any of claims 15-23, wherein the induction of an immune response is used to treat, prevent or ameliorate a disease associated with the immune system.
- 10
30. The method of claim 29, wherein the disease associated with the immune system is an autoimmune disorder.
31. The method of claim 29, wherein the disease associated with the immune system is an immune system deficiency.
- 15
32. The method of any of claims 15-23, wherein the induction of an immune response is used in antisense therapy, and the oligodeoxynucleotide is administered either alone or in combination with an antisense agent.
- 20
33. The method of any of claims 15-23, wherein the induction of an immune response is used to treat, prevent, or ameliorate an infection, and the oligodeoxynucleotide is administered either alone or in combination with an anti-infectious agent.
- 25
34. The method of any of claims 15-23, wherein the induction of an immune response is used to treat, prevent, or ameliorate the symptoms resulting from exposure to a bio-warfare agent.
- 30
35. The method of any of claims 15-34, wherein the method further comprises:
- (a) administering the oligodeoxynucleotide to lymphocytes *ex vivo*, thereby producing activated lymphocytes, and

(b) administering the activated lymphocytes obtained in step (a) to the host.

36. The method of any of claims 15-34, wherein the host is a human.

## SEQUENCE LISTING

<110> Klinman, Dennis  
Verthelyi, Daniela  
Ishii, Ken

<120> OLIGODEOXYNUCLEOTIDE AND ITS USE TO INDUCE AN IMMUNE RESPONSE

<130> 175900

<140> US

<141> 1999-04-12

<160> 143

<170> PatentIn Ver. 2.0

<210> 1

<211> 12

<212> DNA

<213> synthetic

<400> 1

tcgagcgttc tc

12

<210> 2

<211> 19

<212> DNA

<213> synthetic

<400> 2

atcgactctc gagcgttct

19

<210> 3

<211> 24

<212> DNA

<213> synthetic

<400> 3

tcgtcgtttt gtcgttttgc tggt

24

<210> 4

<211> 14

<212> DNA

<213> synthetic

<400> 4

tctcgagcgt tctc

14

<210> 5

<211> 19

<212> DNA

<213> synthetic

<400> 5



tcgactctcg agcggttctc 19

<210> 6  
<211> 20  
<212> DNA  
<213> synthetic

<400> 6

atcgactagc gttcggttctc 20

<210> 7  
<211> 16  
<212> DNA  
<213> synthetic

<400> 7

actctcgagc gttctc 16

<210> 8  
<211> 15  
<212> DNA  
<213> synthetic

<400> 8

ctctcgagcg ttctc 15

<210> 9  
<211> 12  
<212> DNA  
<213> synthetic

<400> 9

gtcgacgttg ac 12

<210> 10  
<211> 12  
<212> DNA  
<213> synthetic

<400> 10

gtcggcggttg ac 12

<210> 11  
<211> 18  
<212> DNA  
<213> synthetic

<400> 11

cgactctcga gcgttctc 18

<210> 12  
<211> 12

<212> DNA  
<213> synthetic  
  
<400> 12  
gtcgacgctg ac 12  
  
<210> 13  
<211> 12  
<212> DNA  
<213> synthetic  
  
<400> 13  
gtcagcgttg ac 12  
  
<210> 14  
<211> 17  
<212> DNA  
<213> synthetic  
  
<400> 14  
gactctcgag cgttctc 17  
  
<210> 15  
<211> 12  
<212> DNA  
<213> synthetic  
  
<400> 15  
gtcgtcgatg ac 12  
  
<210> 16  
<211> 20  
<212> DNA  
<213> synthetic  
  
<400> 16  
atgcactctc gagcgttctc 20  
  
<210> 17  
<211> 13  
<212> DNA  
<213> synthetic  
  
<400> 17  
ctcgagcggtt ctc 13  
  
<210> 18  
<211> 12  
<212> DNA  
<213> synthetic  
  
<400> 18

tgcagcggttc tc 12

<210> 19  
<211> 12  
<212> DNA  
<213> synthetic  
<400> 19

tttggcggttt tt 12

<210> 20  
<211> 20  
<212> DNA  
<213> synthetic  
<400> 20

atcgactctc gagcggttctc 20

<210> 21  
<211> 20  
<212> DNA  
<213> synthetic  
<400> 21

agcggtttctc gatcgacctc 20

<210> 22  
<211> 19  
<212> DNA  
<213> synthetic  
<400> 22

ggtgcaccga tgcagggggg 19

<210> 23  
<211> 14  
<212> DNA  
<213> synthetic  
<400> 23

gtcgtcgacg acgg 14

<210> 24  
<211> 12  
<212> DNA  
<213> synthetic  
<400> 24

gggggcggttg gg 12

<210> 25  
<211> 20  
<212> DNA

<213> synthetic

<400> 25

atgcactctg cagcgttctc

20

<210> 26

<211> 20

<212> DNA

<213> synthetic

<400> 26

atgcactctc gaggcttctc

20

<210> 27

<211> 17

<212> DNA

<213> synthetic

<400> 27

ggtgcatcga tgcaggg

17

<210> 28

<211> 25

<212> DNA

<213> synthetic

<400> 28

gggtcgtcgt tttgtcgttt cgttg

25

<210> 29

<211> 12

<212> DNA

<213> synthetic

<400> 29

aaaggcgtta aa

12

<210> 30

<211> 12

<212> DNA

<213> synthetic

<400> 30

cccggcggtc cc

12

<210> 31

<211> 12

<212> DNA

<213> synthetic

<400> 31

gtcatcgatg ca

12

<210> 32  
<211> 20  
<212> DNA  
<213> synthetic

<400> 32

ggtgcatcga tgcagggggg 20

<210> 33  
<211> 20  
<212> DNA  
<213> synthetic

<400> 33

ggggtcatcg atgaaaaaaaa 20

<210> 34  
<211> 20  
<212> DNA  
<213> synthetic

<400> 34

ggtgcatcga tgcagggggg 20

<210> 35  
<211> 20  
<212> DNA  
<213> synthetic

<400> 35

aaggtcaacg ttgaaaaaaaa 20

<210> 36  
<211> 20  
<212> DNA  
<213> synthetic

<400> 36

aaggtcatcg atgggggggg 20

<210> 37  
<211> 20  
<212> DNA  
<213> synthetic

<400> 37

ggtgcatcga tgcagggggg 20

<210> 38  
<211> 20  
<212> DNA  
<213> synthetic

&lt;400&gt; 38

gggtgcatcga tgcagggggg

20

&lt;210&gt; 39

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; synthetic

&lt;400&gt; 39

gggtgcgtcga cgcagggggg

20

&lt;210&gt; 40

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; synthetic

&lt;400&gt; 40

gggtgcgtcga tgcagggggg

20

&lt;210&gt; 41

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; synthetic

&lt;400&gt; 41

gggtgcgtcga cgcagggggg

20

&lt;210&gt; 42

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; synthetic

&lt;400&gt; 42

gggtgcaccgg tgcagggggg

20

&lt;210&gt; 43

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; synthetic

&lt;400&gt; 43

gggtgcatcga tgcagggggg

20

&lt;210&gt; 44

&lt;211&gt; 12

&lt;212&gt; DNA

&lt;213&gt; synthetic

&lt;400&gt; 44

gtcaacgtcg ac

12

<210> 45  
<211> 12  
<212> DNA  
<213> synthetic

<400> 45

gtcggcgctcg ac

12

<210> 46  
<211> 19  
<212> DNA  
<213> synthetic

<400> 46

ggggtcaacg ttgaggggg

19

<210> 47  
<211> 12  
<212> DNA  
<213> synthetic

<400> 47

gtcggcgctg ac

12

<210> 48  
<211> 20  
<212> DNA  
<213> synthetic

<400> 48

atgcactctc gaggcttctc

20

<210> 49  
<211> 17  
<212> DNA  
<213> synthetic

<400> 49

aatgcatcga tgcaaaa

17

<210> 50  
<211> 12  
<212> DNA  
<213> synthetic

<400> 50

gtcagcgctcg ac

12

<210> 51  
<211> 12  
<212> DNA  
<213> synthetic

&lt;400&gt; 51

gtcaacgttg ac

12

&lt;210&gt; 52

&lt;211&gt; 12

&lt;212&gt; DNA

&lt;213&gt; synthetic

&lt;400&gt; 52

tgcacgatg ca

12

&lt;210&gt; 53

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; synthetic

&lt;400&gt; 53

ggtgcatcga tgcaggggg

19

&lt;210&gt; 54

&lt;211&gt; 12

&lt;212&gt; DNA

&lt;213&gt; synthetic

&lt;400&gt; 54

gtcgacgtcg ac

12

&lt;210&gt; 55

&lt;211&gt; 12

&lt;212&gt; DNA

&lt;213&gt; synthetic

&lt;400&gt; 55

gtcgacgccg ac

12

&lt;210&gt; 56

&lt;211&gt; 12

&lt;212&gt; DNA

&lt;213&gt; synthetic

&lt;400&gt; 56

cccaacgttc cc

12

&lt;210&gt; 57

&lt;211&gt; 12

&lt;212&gt; DNA

&lt;213&gt; synthetic

&lt;400&gt; 57

gtcaacgctg ac

12

&lt;210&gt; 58



<211> 10  
<212> DNA  
<213> synthetic

<400> 58

gagcgttctc

10

<210> 59  
<211> 12  
<212> DNA  
<213> synthetic

<400> 59

gggaacgttg gg

12

<210> 60  
<211> 12  
<212> DNA  
<213> synthetic

<400> 60

gtcagcgctg ac

12

<210> 61  
<211> 16  
<212> DNA  
<213> synthetic

<400> 61

gggggaacgt tcgggg

16

<210> 62  
<211> 12  
<212> DNA  
<213> synthetic

<400> 62

gtcggcgccg ac

12

<210> 63  
<211> 16  
<212> DNA  
<213> synthetic

<400> 63

ggggtaacgt tagggg

16

<210> 64  
<211> 12  
<212> DNA  
<213> synthetic

<400> 64

gtcaacgccg ac 12

<210> 65  
<211> 12  
<212> DNA  
<213> synthetic

<400> 65

tgccctcgagg ca 12

<210> 66  
<211> 12  
<212> DNA  
<213> synthetic

<400> 66

tttaacgttt tt 12

<210> 67  
<211> 12  
<212> DNA  
<213> synthetic

<400> 67

aaaaacgtta aa 12

<210> 68  
<211> 16  
<212> DNA  
<213> synthetic

<400> 68

gggggaagct tcgggg 16

<210> 69  
<211> 12  
<212> DNA  
<213> synthetic

<400> 69

gtcagcgccg ac 12

<210> 70  
<211> 11  
<212> DNA  
<213> synthetic

<400> 70

cgagcgttct c 11

<210> 71  
<211> 16

<212> DNA  
<213> synthetic

<400> 71

ggtgcatcga tgcagg

16

<210> 72  
<211> 20  
<212> DNA  
<213> synthetic

<400> 72

ggtgcatcga tgcagggggg

20

<210> 73  
<211> 19  
<212> DNA  
<213> synthetic

<400> 73

ggtgcatcga tgcagggggg

19

<210> 74  
<211> 13  
<212> DNA  
<213> synthetic

<400> 74

ggcgtcgacg ggg

13

<210> 75  
<211> 19  
<212> DNA  
<213> synthetic

<400> 75

ggtgcgctcg tgcagggggg

19

<210> 76  
<211> 19  
<212> DNA  
<213> synthetic

<400> 76

ggtgcgccga tgcagggggg

19

<210> 77  
<211> 16  
<212> DNA  
<213> synthetic

<400> 77

gggggatcga tcgggg

16

<210> 78  
<211> 13  
<212> DNA  
<213> synthetic

&lt;400&gt; 78

ggggtcgaca ggg

13

<210> 79  
<211> 19  
<212> DNA  
<213> synthetic

&lt;400&gt; 79

ggtgcgtcgg tgcagggggg

19

<210> 80  
<211> 16  
<212> DNA  
<213> synthetic

&lt;400&gt; 80

gggggatgca tcgggg

16

<210> 81  
<211> 20  
<212> DNA  
<213> synthetic

&lt;400&gt; 81

ggtgcgtcga tgcagggggg

20

<210> 82  
<211> 20  
<212> DNA  
<213> synthetic

&lt;400&gt; 82

ggtgcgtcga tgcagggggg

20

<210> 83  
<211> 19  
<212> DNA  
<213> synthetic

&lt;400&gt; 83

ggtgcgtcga tgcagggggg

19

<210> 84  
<211> 19  
<212> DNA

<213> synthetic

<400> 84

ggtgcctcga ggcaggggg

19

<210> 85

<211> 16

<212> DNA

<213> synthetic

<400> 85

gggggctcga gagggg

16

<210> 86

<211> 16

<212> DNA

<213> synthetic

<400> 86

gggggtatcga tagggg

16

<210> 87

<211> 19

<212> DNA

<213> synthetic

<400> 87

ggtgcatcga tgcgagaga

19

<210> 88

<211> 19

<212> DNA

<213> synthetic

<400> 88

ggtgcatcga cgcaggggg

19

<210> 89

<211> 20

<212> DNA

<213> synthetic

<400> 89

gggggtcaacg ttgagggggg

20

<210> 90

<211> 20

<212> DNA

<213> synthetic

<400> 90

ggtgcatgca tgcagggggg

20

<210> 91  
<211> 20  
<212> DNA  
<213> synthetic

<400> 91

ggggtcaagc ttgagggggg

20

<210> 92  
<211> 16  
<212> DNA  
<213> synthetic

<400> 92

ggggtaagct tagggg

16

<210> 93  
<211> 17  
<212> DNA  
<213> synthetic

<400> 93

ggtgcatgca tgcaggg

17

<210> 94  
<211> 20  
<212> DNA  
<213> synthetic

<400> 94

ggtgcataaa tgcagggggg

20

<210> 95  
<211> 17  
<212> DNA  
<213> synthetic

<400> 95

aatgcatgca tgcaaaa

17

<210> 96  
<211> 20  
<212> DNA  
<213> synthetic

<400> 96

ggtgcatgca tgcagggggg

20

<210> 97  
<211> 20  
<212> DNA  
<213> synthetic

<400> 97  
atcgactctg caggcttctc 20  
    <210> 98  
    <211> 12  
    <212> DNA  
    <213> synthetic  
    <400> 98  
tcgaggcttc tc 12  
    <210> 99  
    <211> 20  
    <212> DNA  
    <213> synthetic  
    <400> 99  
atgcactctg caggcttctc 20  
    <210> 100  
    <211> 12  
    <212> DNA  
    <213> synthetic  
    <400> 100  
tgcaggcttc tc 12  
    <210> 101  
    <211> 12  
    <212> DNA  
    <213> synthetic  
    <400> 101  
tcgtttgttc tc 12  
    <210> 102  
    <211> 12  
    <212> DNA  
    <213> synthetic  
    <400> 102  
acgagggttc tc 12  
    <210> 103  
    <211> 13  
    <212> DNA  
    <213> synthetic  
    <400> 103  
ttccttcgag ctc 13

<210> 104  
<211> 12  
<212> DNA  
<213> synthetic

<400> 104

tcgatgcttc tc

12

<210> 105  
<211> 12  
<212> DNA  
<213> synthetic

<400> 105

gcgaggcttc tc

12

<210> 106  
<211> 12  
<212> DNA  
<213> synthetic

<400> 106

ccgaggcttc tc

12

<210> 107  
<211> 12  
<212> DNA  
<213> synthetic

<400> 107

tgcaggcttc tc

12

<210> 108  
<211> 12  
<212> DNA  
<213> synthetic

<400> 108

tcgttcgcttc tc

12

<210> 109  
<211> 12  
<212> DNA  
<213> synthetic

<400> 109

tcgccgcttc tc

12

<210> 110  
<211> 12  
<212> DNA  
<213> synthetic



<400> 110

tcgaatgttc tc

12

<210> 111

<211> 12

<212> DNA

<213> synthetic

<400> 111

tcgagtgttc tc

12

<210> 112

<211> 12

<212> DNA

<213> synthetic

<400> 112

tcgtatgttc tc

12

<210> 113

<211> 12

<212> DNA

<213> synthetic

<400> 113

tcggatgttc tc

12

<210> 114

<211> 12

<212> DNA

<213> synthetic

<400> 114

tcgcatgttc tc

12

<210> 115

<211> 12

<212> DNA

<213> synthetic

<400> 115

tcgactgttc tc

12

<210> 116

<211> 12

<212> DNA

<213> synthetic

<400> 116

tcgcctgttc tc

12

<210> 117

<211> 12  
<212> DNA  
<213> synthetic

<400> 117

tcggctgttc tc

12

<210> 118  
<211> 12  
<212> DNA  
<213> synthetic

<400> 118

tcgtctgttc tc

12

<210> 119  
<211> 12  
<212> DNA  
<213> synthetic

<400> 119

tcgtgtgttc tc

12

<210> 120  
<211> 12  
<212> DNA  
<213> synthetic

<400> 120

tcgcttggttc tc

12

<210> 121  
<211> 12  
<212> DNA  
<213> synthetic

<400> 121

ttgttcgaac tc

12

<210> 122  
<211> 12  
<212> DNA  
<213> synthetic

<400> 122

ttgttcgctc tc

12

<210> 123  
<211> 12  
<212> DNA  
<213> synthetic

<400> 123

ttgttcgccc tc	12
<210> 124	
<211> 12	
<212> DNA	
<213> synthetic	
<400> 124	
ttgttcgggc tc	12
<210> 125	
<211> 12	
<212> DNA	
<213> synthetic	
<400> 125	
ttgttcgttc tc	12
<210> 126	
<211> 12	
<212> DNA	
<213> synthetic	
<400> 126	
ttgttcgtac tc	12
<210> 127	
<211> 12	
<212> DNA	
<213> synthetic	
<400> 127	
tcgagttcgc tc	12
<210> 128	
<211> 12	
<212> DNA	
<213> synthetic	
<400> 128	
tcgagttcgt tc	12
<210> 129	
<211> 12	
<212> DNA	
<213> synthetic	
<400> 129	
tcgagttcga gc	12
<210> 130	
<211> 12	

<212> DNA  
<213> synthetic

<400> 130

ctcgtttggt ct 12

<210> 131  
<211> 12  
<212> DNA  
<213> synthetic

<400> 131

ttcgtttggt ct 12

<210> 132  
<211> 12  
<212> DNA  
<213> synthetic

<400> 132

cccgtttggt ct 12

<210> 133  
<211> 12  
<212> DNA  
<213> synthetic

<400> 133

tcggttggtc tc 12

<210> 134  
<211> 11  
<212> DNA  
<213> synthetic

<400> 134

tgcgcaagg g 11

<210> 135  
<211> 12  
<212> DNA  
<213> synthetic

<400> 135

tcgcccttc tc 12

<210> 136  
<211> 20  
<212> DNA  
<213> synthetic

<400> 136

ggtatatcga tatagggggg 20  
<210> 137  
<211> 20  
<212> DNA  
<213> synthetic  
<400> 137

ggtggatcga tccagggggg 20  
<210> 138  
<211> 20  
<212> DNA  
<213> synthetic  
<400> 138

ggtccatcga tccagggggg 20  
<210> 139  
<211> 20  
<212> DNA  
<213> synthetic  
<400> 139

ggtggatcga tggagggggg 20  
<210> 140  
<211> 11  
<212> DNA  
<213> synthetic  
<400> 140

agcgctaggg g 11  
<210> 141  
<211> 20  
<212> DNA  
<213> synthetic  
<400> 141

ggtgcatgta tgcagggggg 20  
<210> 142  
<211> 20  
<212> DNA  
<213> synthetic  
<400> 20

ggtgcacgcg tgcagggggg 20  
<210> 143  
<211> 13  
<212> DNA

WO 00/61151

PCT/US00/09839

23

<213> synthetic

<400> 143

cgttctcggg ggg

13

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record.**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

